Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 216 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Study Finds Light Therapy Helps Radiation-Related Skin Damage Heal 50% Faster February 3, 2022 Easing Concerns about Giving Research Study Participants Their Genetic Test Results June 1, 2018 Drug Combination May Have Potential for Cancers with TP53 Mutations April 4, 2024 A New Era of Early Cancer Detection With Blood Test May... September 11, 2022 Load more HOT NEWS Carriers of a Germline Pathogenic Variant in CDKN2A are at a... Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung... Young Tulsa Mom Grows Closer To Her Own Mom During Almost... After Misdiagnosis, Mom Found Out She Had Terminal Breast Cancer Shortly...
